Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 7Urogenital Neoplasms 1Prostatic Diseases 1Prostate Cancer Metastatic 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1

Interventions

radium Ra 223 dichloride 2pembrolizumab 2enzalutamide 2abiraterone 2Injections 2Abiraterone Acetate 2niraparib 1efineptakin alfa 1darolutamide 1capivasertib 1cabazitaxel 1apalutamide 1Solutions 1Radium-223 1Prednisone 1Pluvicto 1PSMA-11 1Lutetium-177 1Lutetium 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer (mCRPC) × Lutetium × Genitourinary × Clear all
NCT07244393 2025-11-24

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Cellbion Co., Ltd.

Phase 1 Not yet recruiting
30 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡